Nrf2 overexpression predicts prognosis and 5-FU resistance in gastric cancer

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 9, 2013, Pages 5231-5235

  Hu, Xiu Feng ^a   Yao, Jun ^a   Gao, She Gan ^a   Wang, Xin Shuai ^a   Peng, Xiu Qing ^a   Yang, Yan Tong ^a   Feng, Xiao Shan ^a  

^a HENAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Drug resistance; Gastric cancer; Nrf2; Prognosis

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; FLUOROURACIL; NFE2L2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR NRF2; TUMOR MARKER;

ADENOCARCINOMA; AGED; DRUG RESISTANCE; FEMALE; GASTRECTOMY; GENE EXPRESSION REGULATION; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MORTALITY; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; STOMACH NEOPLASMS; TUMOR CELL LINE;

ADENOCARCINOMA; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; GASTRECTOMY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MULTIVARIATE ANALYSIS; NF-E2-RELATED FACTOR 2; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84887584700     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.9.5231     Document Type: Article

References (20)

1. Ajani JA, Moiseyenko VM, Tjulandin S, et al (2007). Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol, 25, 3205-9.
2. Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917.
3. Huang JY, Xu YY, Sun Z, et al (2012). Comparison different methods of intraoperative and intraperitoneal chemotherapy for patients with gastric cancer: a meta-analysis. Asian Pac J Cancer Prev, 13, 4379-85.
4. Inoue D, Suzuki T, Mitsuishi Y, et al (2012). Accumulation of p62/SQSTM1 is associated with poor prognosis in patients with lung adenocarcinoma. Cancer Sci, 103, 760-6.
5. Jala VR, Radde BN, Haribabu B, Klinge CM (2012). Enhanced expression of G-protein coupled estrogen receptor (GPER/GPR30) in lung cancer. BMC Cancer, 12, 624.
6. Lau A, Villeneuve NF, Sun Z, Wong PK, Zhang DD (2008). Dual roles of Nrf2 in cancer. Pharmacol Res, 58, 262-70.
7. Ma X, Zhang J, Liu S, et al (2012). Nrf2 knockdown by shRNA inhibits tumor growth and increases efficacy of chemotherapy in cervical cancer. Cancer Chemother Pharmacol, 69, 485-94.
8. Merikallio H, Pääkkö P, Kinnula VL, Harju T, Soini Y (2012). Nuclear factor erythroid-derived 2-like 2 (Nrf2) and DJ1 are prognostic factors in lung cancer. Hum Pathol, 43, 577-84.
9. Shelton P, Jaiswal AK (2013). The transcription factor NF-E2-related factor 2 (Nrf2): a protooncogene? FASEB J, 27, 414-23.
10. Shibata T, Kokubu A, Saito S, et al (2011). NRF2 mutation confers malignant potential and resistance to chemoradiation therapy in advanced esophageal squamous cancer. Neoplasia, 13, 864-73.
11. Singh A, Bodas M, Wakabayashi N, Bunz F, Biswal S (2010). Gain of Nrf2 function in non-small-cell lung cancer cells confers radioresistance. Antioxid Redox Signal, 13, 1627-37.
12. Solis LM, Behrens C, Dong W, et al (2010). Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin Cancer Res, 6, 3743-53.
13. Therasse P, Arbuck SG, Eisenhauer EA, et al (2000). New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst, 92, 205-16.
14. Wagner AD, GrotheW, Haerting J, et al (2006). Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol, 24, 2903-9.
15. Wang XJ, Sun Z, Villeneuve NF, et al (2008). Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis, 29, 1235-43.
16. Yamamoto K, Fujiwara Y, Nishida T, et al (2009). Induction chemotherapy with docetaxel, 5-FU and CDDP (DFP) for advanced gastric cancer. Anticancer Res, 29, 4211-5.
17. Yang H, Wang W, Zhang Y, et al (2011). The role of NF-E2-related factor 2 in predicting chemoresistance and prognosis in advanced non-small-cell lung cancer. Clin Lung Cancer, 12, 166-71.
18. Yoichiro Mitsuishi, Hozumi Motohashi, Masayuki Yamamoto (2012). The Keap1-Nrf2 system in cancers: stress response and anabolic metabolism. Front Oncol, 2, 200.
19. Zhang DD (2010). The Nrf2-Keap1-ARE signaling pathway: The regulation and dual function of Nrf2 in cancer. Antioxid Redox Signal, 13, 1623-6.
20. Zhang P, Singh A, Yegnasubramanian S, et al (2010). Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth. Mol Cancer Ther, 9, 336-46.